First patient dosed in trial of huCART19-IL18 cells in the treatment of heme cancers
“BlueWhale Bio is developing a portfolio of critical materials that brings the full benefits of higher-performing cell therapies faster to more patients and at lower costs,” said Peter Keller, Chief Executive Officer at BlueWhale Bio. “Our Synecta technology platform helps address the current limitations in the activation and expansion steps of cell manufacturing by mimicking the physiological stimulation of immune cells.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.